Chugai Signals Cell Therapy Interest Via Athersys Deal
This article was originally published in PharmAsia News
The U.S. venture Athersys has entered into a cell therapy alliance with Chugai that will enable it to take advantage of the newly supportive regulatory environment in Japan for regenerative medicines and to access a potentially large market.
You may also be interested in...
Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.